

Application No. 09/277,229
Amdt. Dated: September 16, 2005
Supplemental Amendment

PATENT APPLICATION**REMARKS**

Claims 11-14 and 22-28 are pending in the subject patent application.

At the examiner's request, applicants respectfully direct the examiner's attention to the originally filed specification, which together with SEQ ID NO:4 provides support for the recitation in claim 11. Specifically, the polypeptide includes the transmembrane domain and identifies the transmembrane domain as spanning amino acids 461-477. (Specification, page 93, lines 12-13). All of the polypeptides recited in claim 11 include these amino acids of the transmembrane domain.


Claim 14 has been amended at the examiner's suggestion to recite "[a]n isolated biologically active polypeptide", support for which may be found in the originally filed specification *inter alia* at page 93, lines 17-18. No new matter has been added by this amendment.

During applicants' December 7, 2005 telephone with the examiner, it was discovered that a discrepancy exists between the U.S. PTO copy of the originally filed specification and applicants' copy of the originally filed specification. Specifically, the U.S. PTO copy differs by two pages, *i.e.*, is shorter by two pages, than applicants' copy. Therefore, in the U.S. PTO copy of the specification, page 91 corresponds to applicants' page 93. Applicants will order a copy of the originally filed specification from the U.S. PTO to ascertain how these discrepancies occurred.

CONCLUSION

In view of the foregoing, it is believed that the subject application is in condition for allowance, a notice of which is earnestly solicited by applicants.

Respectfully submitted,



Date: December 7, 2005

Estelle J. Tseydos
Attorney for Applicants
Registration No.: 31,145
Phone: (212) 309-1021
Fax: (212) 309-1100

Please send all future correspondence to:

Hunton & Williams LLP
200 Park Avenue, 52nd Floor
New York, New York 10166-0005